TB-500
Thymosin Beta-4 Fragment
TB-500 is a synthetic peptide related to thymosin beta-4, investigated for its potential to promote healing and tissue repair. Direct human evidence is minimal, and it is not FDA-approved.
TB-500
Thymosin Beta-4 Fragment (marketed)Half-Life
Not established
Route
Not established
Typical Dose
Not established
Mechanism / Target
Not established
Evidence Level
Preclinical
Primary Research Use
In vitro wound healing
Mechanism: Promotes cell migration and angiogenesis by binding to actin and regulating the cytoskeleton.
This information is for research only. Not intended for human use.
Overview
TB-500 is a marketed synthetic peptide product promoted as related to thymosin beta-4 (TB4), a 43-amino-acid endogenous peptide that regulates actin, cell migration, angiogenesis, and repair signaling . It is not a standardized pharmaceutical entity, and its identity can vary across products. The term "TB-500" functions primarily as a commercial designation for peptide products linked to TB4, with reports of misbranding and adulteration .
In the research literature, direct TB-500 evidence is minimal. Among 80 studies on TB4/TB-500 in healing and regeneration, only one directly examined TB-500—a 2024 study focused on metabolite profiling and in-vitro fibroblast wound-healing activity . Most claims about TB-500's benefits are extrapolated from the more extensive TB4 preclinical literature, which shows repair-related effects in cell migration, blood vessel growth (angiogenesis), inflammatory modulation, and extracellular matrix remodeling . No human clinical trials have directly tested TB-500 for musculoskeletal injuries such as tendon, ligament, or muscle repair .
How it works
The mechanism of TB-500 is largely inferred from thymosin beta-4 (TB4) biology, not direct human TB-500 data . If the marketed compound behaves like TB4 fragments, it may promote tissue repair by enhancing cell movement into injured areas, stimulating new blood vessel formation, and dampening excessive inflammation .
Actin regulation and cell migration
TB4 is an actin-binding peptide, and the literature consistently links TB4-related repair to cytoskeletal remodeling and cell migration . For TB4, this includes activation of endothelial progenitor cell migration through PI3K/Akt/eNOS signaling and myoblast chemotaxis . Direct TB-500 evidence is limited to fibroblast wound-healing assays, which showed that TB-500-related metabolites support closure in cell cultures .
Angiogenesis
Angiogenesis (new blood vessel growth) is one of the most cited secondary mechanisms, proposed to improve nutrient and oxygen delivery to damaged tissue . Proposed mediators include VEGF, HIF-1α stabilization, and Notch signaling .
Inflammatory modulation
TB4-related peptides can suppress inflammatory signals, potentially shifting tissue from a prolonged inflammatory state toward remodeling .
ECM remodeling
Some studies suggest TB4 influences collagen organization and matrix metalloproteinase activity, which may affect tissue quality .
Pharmacokinetics in humans are unknown; no half-life or bioavailability data exist for TB-500 .
Documented effects
Direct evidence for TB-500's effects in humans is absent. One study demonstrated that TB-500 metabolites accelerated fibroblast wound closure in vitro . Beyond that, all described effects come from thymosin beta-4 (TB4) research or community reports.
Documented in vitro effects
- Fibroblast wound closure: TB-500-related metabolites increased the rate at which fibroblasts closed a scratch wound in cell culture .
Effects from TB4 literature (preclinical)
- Angiogenesis: TB4 stimulates new blood vessel growth in animal models, which may improve tissue oxygenation .
- Cell migration: Endothelial cells and myoblasts migrate faster in the presence of TB4, aiding repair .
- Inflammatory modulation: TB4 can reduce inflammatory cytokine levels and suppress NF-κB signaling .
- Tissue remodeling: In some models, TB4 promotes better collagen organization and reduces fibrosis .
No study has directly shown that TB-500 improves healing in human tendons, ligaments, or muscles. Any real-world effects reported are unvalidated and may stem from natural recovery or placebo .
Research protocols
No human clinical trials have established a standard dosing protocol for TB-500. All current protocols come from community practice and are not evidence-based .
Typical community protocols
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| Loading phase | 2–2.5 mg | Twice weekly | 4–6 weeks |
| Maintenance | 1–2 mg | Every 1–2 weeks | 4–8 weeks |
| Conservative start | 1–2 mg | Twice weekly | 2 weeks, then reassess |
This information is for research only. Not intended for human use.
These are administered subcutaneously or intramuscularly. Some practitioners use body weight as a rough guide (0.04–0.08 mg/kg/week during loading) [community protocol].
Important caveats
- Product quality varies; misbranding and adulteration have been documented .
- No human pharmacokinetic data exist, so dose selection is empirical .
- No superiority of intramuscular over subcutaneous route has been shown [community protocol].
Refer to the interactive reconstitution calculator for precise volume-to-dose conversions.
Loading
Community protocol; not validated in controlled trials.
Maintenance
Optional extension if benefit persists.
This information is for research only. Not intended for human use.
Reconstitution and storage
TB-500 is typically supplied as a lyophilized powder in 5 mg or 10 mg vials. Bacteriostatic water is the standard diluent for multi‐dose use. Because direct stability studies specific to TB-500 are lacking, handling follows general peptide guidelines .
Reconstitution steps
- Allow vial and diluent to reach room temperature.
- Swab stoppers with alcohol.
- Inject diluent slowly down the vial wall; avoid foaming.
- Swirl gently to dissolve; do not shake.
- Discard if solution is cloudy or contains particles.
Common diluent volumes
| Vial size | Diluent volume | Final concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
| 10 mg | 4 mL | 2.5 mg/mL |
This information is for research only. Not intended for human use.
Use the reconstitution calculator to determine the exact volume for any desired dose. Do not pre-mix large volumes or store in syringes.
Storage
- Lyophilized powder: 2–8°C (refrigerated) for months; –20°C for longer term.
- Reconstituted solution: 2–8°C; use within 28–30 days (bacteriostatic water) or 7–14 days (sterile water).
- Minimize freeze-thaw cycles and protect from light.
Concentration
25 mcg / unit
Draw Volume
100 units (1 ml)
Doses Per Vial
2 doses
Total Solution
200 units (2 ml)
This information is for research only. Not intended for human use.
Interactions
TB-500 has no formal drug-interaction studies, so all concerns are theoretical or extrapolated from thymosin beta-4 biology .
Potential interactions
| Drug/Class | Concern | Rationale |
|---|---|---|
| Anticoagulants/antiplatelets | Increased bleeding risk | TB-500's angiogenic and fibrin-interacting properties may alter hemostasis [source:1]. |
| NSAIDs | May blunt repair signaling | NSAIDs reduce inflammation, which could interfere with repair cascades [source:1][source:3]. |
| Corticosteroids | Counteract repair effects | Steroids suppress fibroblast activity and angiogenesis [source:1][source:3]. |
| Chemotherapy | Avoid | Pro-migratory/angiogenic effects risk supporting tumor growth [source:1][source:3]. |
This information is for research only. Not intended for human use.
Condition-specific cautions
- Surgery: Stop use preoperatively due to uncertain wound healing effects .
- Cancer history: Use only with oncology oversight .
- Pregnancy/breastfeeding: Avoid; no safety data .
- Athletes: TB-500 is prohibited under WADA rules .
Cycling and tolerance
Cycling TB-500 is a practical measure, not one supported by direct evidence. The main rationale is to limit exposure to an unstandardized product with unknown long-term safety .
Typical cycle patterns
| Cycle type | Duration | Protocol |
|---|---|---|
| Standard | 4–6 weeks loading | 2–2.5 mg twice weekly, then stop |
| Extended | 6–12 weeks | Loading (4–6 weeks) followed by maintenance (1–2 mg every 1–2 weeks) |
| Short pulse | 4 weeks | 2 mg weekly, then stop |
This information is for research only. Not intended for human use.
Off-periods of 4–8 weeks are common after a cycle. There is no evidence of receptor desensitization; cycling is simply precautionary .
Signs to pause
- No further functional improvement after 4–6 weeks.
- New or worsening side effects (flushing, headache, injection-site irritation).
- Inability to verify product source or purity.
- Upcoming surgery or perioperative period .
Stacking
TB-500 is often combined with other peptides, but no controlled studies validate these stacks. The combinations below are based on community practice and mechanistic overlap.
Common stacks
- BPC‑157: The most frequent pair. Both are thought to support soft‑tissue repair, but evidence is weak for both .
- GH secretagogues (CJC‑1295, ipamorelin): Used for added anabolic/recovery effects. However, no orthopaedic trials show superior healing, and additive side effects (edema, glucose changes) can complicate monitoring .
- GHK‑Cu: Overlaps in wound‑healing and anti‑inflammatory signaling, but no direct combination data exist .
- Thymosin alpha‑1: Sometimes stacked for immune support, but evidence is anecdotal.
Practical concerns
- More peptides mean more injections, higher sterility risk, and difficulty attributing benefits or side effects.
- Start one agent at a time, monitor response, and use only from verified sources .
Regulatory status
TB-500 is not FDA‑approved for any indication. It is characterized in the literature as an unapproved, marketed derivative of thymosin beta‑4 with minimal clinical evidence .
United States
- No FDA approval, no DEA scheduling, no recognized compounding monograph .
- Products are typically sold through gray‑market channels, raising concerns about misbranding and adulteration .
International
- No EMA or other national health authority approval .
- Importation often falls into a legal gray area; customs seizure risk is high.
Sports & Anti‑Doping
- TB-500 is classified as a prohibited substance by WADA (under the S2 category) and is banned at all times .
- Athletes should avoid it entirely due to both performance‑enhancing claims and analytical detection capabilities .
Safety and side effects
Direct human safety data for TB-500 are lacking. What is known comes largely from thymosin beta‑4 (TB4) phase‑I studies and from community reports .
Common side effects (community‑reported)
- Injection‑site pain, redness, or swelling
- Transient flushing, headache, nausea, or fatigue
- Lightheadedness
Uncommon / theoretical concerns
- Edema or fluid retention
- Altered wound healing pattern
- Mast‑cell activation (itching, rash)
- Theoretical risk of promoting occult malignancy due to pro‑angiogenic signals
Product‑quality risks
Analytical studies have documented misbranding and adulteration in products labeled as TB‑500/TB‑1000. This creates risks of contamination, incorrect dosing, and exposure to unknown substances . Always inspect injection sites and seek medical attention for fever, spreading redness, or systemic symptoms.
Contraindications
- Active cancer or recent cancer history (avoid)
- Planned surgery (stop preoperatively)
- Pregnancy or breastfeeding (avoid)
- Bleeding disorders or anticoagulant use (caution)
No long‑term safety data exist; short, finite cycles are more defensible than continuous use .
Frequently asked questions
Is TB-500 FDA-approved?+
No. Direct TB-500 is not FDA-approved for any indication, and the orthopaedic literature characterizes it as an unapproved, marketed thymosin beta-4 derivative with minimal verifiable clinical evidence (review/scoping review). Human clinical studies in the literature are concentrated on thymosin beta-4 products, not TB-500 itself. Product identity is an added issue: analyses of commercial TB500/TB1000 products found misbranding/adulteration concerns, so label claims should not be assumed to reflect actual contents (analytical study).
What exactly is TB-500, and is TB-500 the same as thymosin beta-4?+
Not exactly. Thymosin beta-4 (TB4) is the native 43-amino-acid peptide studied in most of the literature, whereas “TB-500” is a commercial designation used for related synthetic peptide products and fragments; the evidence base does not establish interchangeability (review/scoping review). In the mapped literature, direct TB-500 evidence was limited to one mixed study focused on metabolite profiling and in-vitro fibroblast wound-healing activity rather than validated human musculoskeletal outcomes (preclinical).
Does TB-500 actually work for tendon, ligament, or muscle healing?+
Evidence is weak for TB-500 specifically. The overall biological rationale comes mostly from TB4 literature showing repair-related effects on cell migration, angiogenesis, inflammation modulation, and matrix remodeling in preclinical models (animal/in-vitro). For direct TB-500, the available published evidence is limited to in-vitro wound-healing screening and rat metabolite work, not human tendon/ligament RCTs or even convincing human observational musculoskeletal data (preclinical). Practical takeaway: plausible mechanism, but no validated human orthopaedic efficacy.
Is subcutaneous or intramuscular better?+
There is no human dose-finding or route-comparison study for TB-500 in musculoskeletal use (review). Community use is typically subcutaneous for systemic exposure and peri-injury subcutaneous/intramuscular for local convenience (community protocol), but that preference is not supported by comparative clinical data. Because commercial products may be mislabeled or adulterated, route choice does not solve the core uncertainty around formulation quality (analytical study).
What dose do people usually use?+
There is no evidence-based human dosing standard for TB-500 in musculoskeletal care (review/scoping review). Common non-study protocols usually use a “loading” phase of 2–2.5 mg twice weekly for 4–6 weeks, then 2–5 mg every 1–4 weeks for maintenance (community protocol). Some practitioners avoid maintenance entirely and use short cycles only during active injury recovery (practitioner consensus). These protocols are extrapolations, not clinically validated regimens.
How long can I take TB-500?+
Published data do not define a safe chronic-use duration for TB-500 (review). Given the absence of long-term human safety data, short finite cycles are more defensible than continuous use (practitioner consensus). The literature repeatedly notes uncertainty regarding long-term safety, product equivalence, dosing, and perioperative implications (review/scoping review).
What are the main safety concerns?+
The biggest real-world risks are evidence gaps and product quality, not just peptide pharmacology (review/analytical study). Concerns include mislabeled concentration or identity, sterility/contamination risk from injectable gray-market products, and unknown long-term systemic effects. Mechanistically related TB4 literature raises theoretical concern that pro-migratory/angiogenic signaling could be problematic in some disease contexts, but this remains largely unquantified for TB-500 in humans (mechanistic/preclinical). Competitive athletes should also note anti-doping risk; TB4 and derivatives including TB-500 are treated as prohibited in sport contexts (review/scoping review).
Can I use TB-500 around surgery, or if I’m pregnant?+
Perioperative use is poorly studied and generally approached conservatively because there are no validated data on wound complications, hematoma, infection risk, or implant-related outcomes in orthopaedic surgery (review). Pregnancy and breastfeeding data are absent for TB-500 specifically; with no reproductive safety evidence, avoidance is the cautious position (evidence gap). For elective surgery, many clinicians would stop nonessential unregulated injectables beforehand due to sterility and attribution concerns rather than known pharmacology alone (practitioner consensus; review).
How does TB-500 compare with BPC-157?+
They are often grouped together in sports medicine discussions, but the evidence profiles are different. TB-500 has extremely limited direct evidence and mostly inherits plausibility from TB4 biology, while BPC-157 has a larger preclinical literature and a small amount of human exploratory data, though still inadequate for strong clinical recommendations (review). Neither has robust human orthopaedic trial support, but TB-500 is the less directly substantiated of the two.
References
- 1.Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping ReviewMcGuire, et al. · 2026
- 2.Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitroRahaman, et al. · 2024
- 3.TB500/TB1000 and SGF1000: A Scientific Approach for a Better Understanding of Misbranded and Adulterated DrugsDelcourt, et al. · 2022
- 4.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceMendias, et al. · 2026
- 5.Emerging Peptide Therapies in Orthopaedics: Evidence, Safety, and Perioperative ImplicationsSiddiqi, et al. · 2026
- 6.Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine PhysiciansMayfield, et al. · 2026
- 7.A first‐in‐human, randomized, double‐blind, single‐ and multiple‐dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteersWang, et al. · 2021
- 8.A randomized, placebo‐controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteersRuff, et al. · 2010
- 9.Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse DetectionDelcourt, et al. · 2024
- 10.Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025Thevis, et al. · 2026
Last reviewed on Jun 22, 2026
Have more questions about TB-500?
Ask ChatPEP for protocols, stacking, and cited research tailored to your goals.